| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_794fd57b87ca3f8829703881985291ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_635ecf9d90e696cd3f5c22693064a5a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ad6aacfc47b6f087025d0f2ff4604c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31e2e21d5388230e5e6580e4c44511c7 |
| publicationDate |
2023-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4124663-A1 |
| titleOfInvention |
Methods for predicting a response to cancer treatment |
| abstract |
The present invention pertains to methods for predicting the response of a patient to an anticancer agent such as a chemotherapeutic agent or an immunotherapeutic agent. The methods according to the invention comprise a step of detecting, in a biological sample obtained from a cancer patient, a mutation in TP53 and/or POT1 genes. The present inventor has indeed demonstrated that the presence of a mutation in TP53 or POT1 is associated with a poor response to immunotherapy or chemotherapy. |
| priorityDate |
2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |